1) Abbas, A.I., Hedlund, P.B., Huang, X.P. et al. : Amisulpride is a potent 5-HT, antagonist, rele- vance for antidepressant actions in vivo. Psycho- pharmacology (Berl) , 205 : 119-128, 2009.
2) Ahlfors, U.G., RimOn, R., Apppelberg, B. et al. : Remoxipride and haloperidol in schizophrenia : a double-blind multicentre study. Acta Psy- chiatr. Scand. Suppl., 358: 99-103, 1990.
3) Andersen, J., Korner, A,. Ostergaard, P. et al. : A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia. Acta Psychiatr. Scand. Suppl., 358: 104-107, 1990.
4) Boyer, P., Lecrubier, Y., Puech, A.J. et al. : Treatment of negative symptoms in schizophre- nia with amisulpride. Br. J. Psychiatry, 166 : 68- 72, 1995.
5) Carriere, P., Bonhomme, D., Lemperiere, T. : Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia : results of a multi- centre, double-blind study. Amisulpride Study Group. Eur. Psychiatry, 15 (5) : 321-329, 2000.